Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) shares fell 6.1% during trading on Tuesday . The company traded as low as $1.69 and last traded at $1.69. Approximately 1,903 shares were traded during trading, a decline of 66% from the average session volume of 5,564 shares. The stock had previously closed at $1.80.
Kiromic BioPharma Trading Down 6.5 %
The firm has a market cap of $2.44 million, a PE ratio of -0.16 and a beta of 1.97. The firm has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $2.38.
Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.74) EPS for the quarter.
Kiromic BioPharma Company Profile
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Featured Articles
- Five stocks we like better than Kiromic BioPharma
- How is Compound Interest Calculated?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Invest in Insurance Companies: A Guide
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.